Current Report Filing (8-k)
December 18 2018 - 8:42AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 18, 2018
Intra-Cellular Therapies, Inc.
(Exact name of registrant as specified in its charter)
Commission
File Number: 001-36274
|
|
|
Delaware
|
|
36-4742850
|
(State or other jurisdiction
of incorporation)
|
|
(IRS Employer
Identification No.)
|
430 East 29
th
Street
New York, New York 10016
(Address of principal executive offices, including zip code)
(646) 440-9333
(Registrants telephone number, including area code)
Not applicable
(Former
name or former address, if changed since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On December 18, 2018, Intra-Cellular Therapies, Inc. (the Company) announced that an independent data monitoring committee (DMC)
had completed a pre-specified interim analysis of the Companys ongoing clinical trial with low-dose lumateperone (9 mg ITI-007) for the treatment of agitation in patients with probable Alzheimers disease (Study 201).
The Companys press release announcing that an independent data monitoring committee (DMC) had completed a pre-specified interim analysis
of the Companys ongoing clinical trial with low-dose lumateperone (9 mg ITI-007) for the treatment of agitation in patients with probable Alzheimers disease (Study 201) is filed as Exhibit 99.1 to this Current Report on Form 8-K and is
incorporated herein by reference.
ITEM 9.01
|
Financial Statements and Exhibits.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
INTRA-CELLULAR THERAPIES, INC.
|
|
|
By:
|
|
/s/ Lawrence J. Hineline
|
|
|
Lawrence J. Hineline
|
|
|
Vice President of Finance, Chief Financial Officer, Treasurer and Assistant Secretary
|
Date: December 18, 2018
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From Apr 2024 to May 2024
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From May 2023 to May 2024